

Ralph R Weichselbaum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5097615/publications.pdf>

Version: 2024-02-01

190
papers

22,163
citations

16791

66
h-index

10679

143
g-index

194
all docs

194
docs citations

194
times ranked

27933
citing authors

#	ARTICLE	IF	CITATIONS
1	Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. <i>Journal of Clinical Investigation</i> , 2014, 124, 687-695.	3.9	1,627
2	STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. <i>Immunity</i> , 2014, 41, 843-852.	6.6	1,468
3	Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. <i>Blood</i> , 2009, 114, 589-595.	0.6	1,146
4	Radiotherapy and immunotherapy: a beneficial liaison?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 365-379.	12.5	760
5	The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity. <i>Cancer Research</i> , 2011, 71, 2488-2496.	0.4	692
6	Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. <i>Nature</i> , 2019, 566, 270-274.	13.7	681
7	Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. <i>Nature Communications</i> , 2016, 7, 12499.	5.8	625
8	p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. <i>Nature</i> , 1999, 399, 814-817.	13.7	551
9	Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 632-641.	3.2	525
10	Nanoscale Metal-Organic Frameworks for Therapeutic, Imaging, and Sensing Applications. <i>Advanced Materials</i> , 2018, 30, e1707634.	11.1	504
11	Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. <i>Nature</i> , 1995, 376, 785-788.	13.7	496
12	An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 18490-18495.	3.3	484
13	Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 1611-1618.	0.8	448
14	Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy. <i>Nature Biomedical Engineering</i> , 2018, 2, 600-610.	11.6	438
15	Chlorin-Based Nanoscale Metal-Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy. <i>Journal of the American Chemical Society</i> , 2016, 138, 12502-12510.	6.6	429
16	Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. <i>Journal of the American Chemical Society</i> , 2016, 138, 16686-16695.	6.6	384
17	Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. <i>Nature Communications</i> , 2017, 8, 1736.	5.8	304
18	Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes. <i>Clinical Cancer Research</i> , 2015, 21, 870-881.	3.2	303

#	ARTICLE	IF	CITATIONS
19	Stereotactic body radiotherapy for multisite extracranial oligometastases. <i>Cancer</i> , 2012, 118, 2962-2970.	2.0	295
20	Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. <i>Oncogene</i> , 2000, 19, 1975-1981.	2.6	284
21	STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 1714-1719.	3.3	273
22	Functional interaction between DNA-PK and c-Abl in response to DNA damage. <i>Nature</i> , 1997, 386, 732-735.	13.7	259
23	Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. <i>Nature Communications</i> , 2018, 9, 2351.	5.8	253
24	The oligometastatic stateâ€”separating truth from wishful thinking. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 549-557.	12.5	245
25	MicroRNA Expression Characterizes Oligometastasis(es). <i>PLoS ONE</i> , 2011, 6, e28650.	1.1	242
26	Targeting the Tumor Microenvironment with Interferon- γ Bridges Innate and Adaptive Immune Responses. <i>Cancer Cell</i> , 2014, 25, 37-48.	7.7	236
27	A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses. <i>Molecular Therapy</i> , 2014, 22, 1048-1055.	3.7	233
28	Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. <i>Nature</i> , 1996, 382, 272-274.	13.7	232
29	Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling. <i>Immunity</i> , 2017, 47, 363-373.e5.	6.6	209
30	Tumour ischaemia by interferon- γ resembles physiological blood vessel regression. <i>Nature</i> , 2017, 545, 98-102.	13.7	199
31	New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology. <i>Science Translational Medicine</i> , 2013, 5, 173sr2.	5.8	197
32	Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. <i>Nature Communications</i> , 2019, 10, 1899.	5.8	195
33	Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. <i>Nature Communications</i> , 2018, 9, 1793.	5.8	188
34	Oligo- and Polymetastatic Progression in Lung Metastasis(es) Patients Is Associated with Specific MicroRNAs. <i>PLoS ONE</i> , 2012, 7, e50141.	1.1	181
35	Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	172
36	Determination of cell fate by c-Abl activation in the response to DNA damage. <i>Oncogene</i> , 1998, 17, 3309-3318.	2.6	160

#	ARTICLE	IF	CITATIONS
37	Non-canonical NF- κ B Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy. <i>Immunity</i> , 2018, 49, 490-503.e4.	6.6	155
38	DNA damage-induced cytotoxicity is mediated by the cooperative interaction of phospho-NF- κ B p50 and a single nucleotide in the κ B-site. <i>Nucleic Acids Research</i> , 2013, 41, 764-774.	6.5	153
39	A Critical Role of the IL-1 β -IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 146-156.	0.3	152
40	Tumor-reprogrammed resident T cells resist radiation to control tumors. <i>Nature Communications</i> , 2019, 10, 3959.	5.8	151
41	The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications. <i>Science Immunology</i> , 2016, 1, .	5.6	149
42	Activation of protein kinase C δ by the c-Abl tyrosine kinase in response to ionizing radiation. <i>Oncogene</i> , 1998, 16, 1643-1648.	2.6	143
43	Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. <i>Oncotarget</i> , 2016, 7, 26496-26515.	0.8	141
44	Radiation as an Immune Modulator. <i>Seminars in Radiation Oncology</i> , 2013, 23, 273-280.	1.0	140
45	Radiation-Induced Equilibrium Is a Balance between Tumor Cell Proliferation and T Cell-Mediated Killing. <i>Journal of Immunology</i> , 2013, 190, 5874-5881.	0.4	140
46	Tumor-associated fibroblasts predominantly come from local and not circulating precursors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 7551-7556.	3.3	139
47	Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). <i>Cancer</i> , 2016, 122, 2242-2250.	2.0	109
48	<i>Lactobacillus rhamnosus</i> GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. <i>Gut</i> , 2022, 71, 521-533.	6.1	108
49	Radiotherapy and Immunotherapy for Cancer: From "Systemic" to "Multisite". <i>Clinical Cancer Research</i> , 2020, 26, 2777-2782.	3.2	103
50	14q32-encoded microRNAs mediate an oligometastatic phenotype. <i>Oncotarget</i> , 2015, 6, 3540-3552.	0.8	103
51	Radiation or surgery for chemodectoma of the temporal bone: A review of local control and complications. <i>Head and Neck</i> , 1990, 12, 303-307.	0.9	101
52	Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. <i>PLoS ONE</i> , 2018, 13, e0195149.	1.1	99
53	Integration of radiotherapy and immunotherapy for treatment of oligometastases. <i>Lancet Oncology</i> , The, 2019, 20, e434-e442.	5.1	98
54	Increasing Radiation Therapy Dose Is Associated With Improved Survival in Patients Undergoing Stereotactic Body Radiation Therapy for Stage I Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 344-350.	0.4	91

#	ARTICLE	IF	CITATIONS
55	Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. <i>Journal of Surgical Oncology</i> , 1991, 46, 31-36.	0.8	89
56	Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 149-157.	1.7	83
57	CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response. <i>Cell Reports</i> , 2017, 18, 2373-2386.	2.9	81
58	Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. <i>Nature Communications</i> , 2020, 11, 4591.	5.8	81
59	Radiation-induced tumour necrosis factor- α expression: clinical application of transcriptional and physical targeting of gene therapy. <i>Lancet Oncology</i> , The, 2002, 3, 665-671.	5.1	80
60	The relationship between expression of PD-L1 and HIF-1 α in glioma cells under hypoxia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 92.	6.9	80
61	Radiobiological Characterization of 53 Human Tumor Cell Lines. <i>International Journal of Radiation Biology</i> , 1989, 56, 553-560.	1.0	78
62	Ultrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy. <i>Matter</i> , 2019, 1, 1331-1353.	5.0	78
63	Loss of Nfkb1 leads to early onset aging. <i>Aging</i> , 2014, 6, 931-942.	1.4	78
64	Fecal microbiota transplant rescues mice from human pathogen mediated sepsis by restoring systemic immunity. <i>Nature Communications</i> , 2020, 11, 2354.	5.8	75
65	Genetically engineered HSV in the treatment of glioma: a review. , 2000, 10, 17-30.		74
66	RAD54 family translocases counter genotoxic effects of RAD51 in human tumor cells. <i>Nucleic Acids Research</i> , 2015, 43, 3180-3196.	6.5	72
67	Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 735-748.	1.7	71
68	Temozolomide Treatment Induces lncRNA MALAT1 in an NF- κ B and p53 Codependent Manner in Glioblastoma. <i>Cancer Research</i> , 2019, 79, 2536-2548.	0.4	71
69	RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E484-91.	3.3	70
70	Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. <i>Clinical Cancer Research</i> , 2016, 22, 2734-2743.	3.2	68
71	From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 20-25.	3.2	67
72	STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability. <i>Cancer Research</i> , 2019, 79, 1465-1479.	0.4	64

#	ARTICLE	IF	CITATIONS
73	Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. <i>Oncotarget</i> , 2016, 7, 43039-43051.	0.8	62
74	Oxygen-Guided Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 977-984.	0.4	59
75	Changing face and different countenances of prostate cancer:Racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. <i>International Journal of Cancer</i> , 2001, 96, 363-371.	2.3	57
76	Function for p300 and not CBP in the apoptotic response to DNA damage. <i>Oncogene</i> , 1999, 18, 5714-5717.	2.6	54
77	Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 691.	1.2	54
78	Western Diet Promotes Intestinal Colonization by Collagenolytic Microbes and Promotes Tumor Formation After Colorectal Surgery. <i>Gastroenterology</i> , 2020, 158, 958-970.e2.	0.6	53
79	CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 20059.	1.6	53
80	<i>BCL3</i> expression promotes resistance to alkylating chemotherapy in gliomas. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	52
81	Integrated molecular and clinical staging defines the spectrum of metastatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 581-588.	12.5	52
82	DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs. <i>Cancer Research</i> , 2019, 79, 650-662.	0.4	52
83	p50 (NF- κ B1) Is an Effector Protein in the Cytotoxic Response to DNA Methylation Damage. <i>Molecular Cell</i> , 2011, 44, 785-796.	4.5	49
84	The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis—From Conception to Treatment. <i>Journal of Clinical Oncology</i> , 2018, 36, 3240-3250.	0.8	49
85	Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable. <i>Radiotherapy and Oncology</i> , 2020, 147, 217-220.	0.3	49
86	Suppression of local type I interferon by gut microbiota—derived butyrate impairs antitumor effects of ionizing radiation. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	49
87	A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 130-140.	0.5	49
88	Radiotherapy and immunotherapy: open questions and future strategies. <i>Trends in Cancer</i> , 2022, 8, 9-20.	3.8	49
89	Synergistic checkpoint-blockade and radiotherapy—radiodynamic therapy via an immunomodulatory nanoscale metal—organic framework. <i>Nature Biomedical Engineering</i> , 2022, 6, 144-156.	11.6	47
90	Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. <i>International Journal of Radiation Biology</i> , 2009, 85, 421-431.	1.0	46

#	ARTICLE	IF	CITATIONS
91	Linking Cancer Metabolism to DNA Repair and Accelerated Senescence. <i>Molecular Cancer Research</i> , 2016, 14, 173-184.	1.5	46
92	Functional role for the c-Abl tyrosine kinase in meiosis. <i>Oncogene</i> , 1998, 16, 1773-1777.	2.6	45
93	Transcriptional Targeting of Adenovirally Delivered Tumor Necrosis Factor β by Temozolomide in Experimental Glioblastoma. <i>Cancer Research</i> , 2004, 64, 6381-6384.	0.4	45
94	Comparison of 3D Conformal Radiotherapy and Intensity Modulated Radiotherapy with or without Simultaneous Integrated Boost during Concurrent Chemoradiation for Locally Advanced Head and Neck Cancers. <i>PLoS ONE</i> , 2014, 9, e94456.	1.1	44
95	Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. <i>Clinical Cancer Research</i> , 2020, 26, 6437-6444.	3.2	43
96	A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. <i>Cancer</i> , 1989, 63, 30-36.	2.0	42
97	In Vivo Delivery and Therapeutic Effects of a MicroRNA on Colorectal Liver Metastases. <i>Molecular Therapy</i> , 2017, 25, 1588-1595.	3.7	42
98	Combination of Linear Accelerator-Based Intensity-Modulated Total Marrow Irradiation and Myeloablative Fludarabine/Busulfan: A Phase I Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2034-2041.	2.0	40
99	Nanoscale metal-organic frameworks for x-ray activated in situ cancer vaccination. <i>Science Advances</i> , 2020, 6, .	4.7	40
100	The oligometastatic spectrum in the era of improved detection and modern systemic therapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 585-599.	12.5	39
101	Inhibition of Nuclear Factor- κ B Activity by Temozolomide Involves <i>O</i> ⁶ -Methylguanine-Induced Inhibition of p65 DNA Binding. <i>Cancer Research</i> , 2007, 67, 6889-6898.	0.4	36
102	The Immunology of Ablative Radiation. <i>Seminars in Radiation Oncology</i> , 2015, 25, 40-45.	1.0	36
103	HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 407-418.	1.9	36
104	Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	35
105	A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. <i>Cancer</i> , 1990, 66, 206-213.	2.0	33
106	The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. <i>Science Immunology</i> , 2021, 6, .	5.6	33
107	A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 487-498.	0.4	29
108	Radiotherapy and immune checkpoint blockade: potential interactions and future directions. <i>Trends in Molecular Medicine</i> , 2015, 21, 463-465.	3.5	28

#	ARTICLE	IF	CITATIONS
109	Protection from Radiation-Induced Pulmonary Fibrosis by Peripheral Targeting of Cannabinoid Receptor-1. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 53, 555-562.	1.4	28
110	E2F Proteins Are Posttranslationally Modified Concomitantly with a Reduction in Nuclear Binding Activity in Cells Infected with Herpes Simplex Virus 1. <i>Journal of Virology</i> , 2000, 74, 7842-7850.	1.5	27
111	Race and competing mortality in advanced head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 40-44.	0.8	27
112	Systemic miRNA delivery by nontoxic nanoscale coordination polymers limits epithelial-to-mesenchymal transition and suppresses liver metastases of colorectal cancer. <i>Biomaterials</i> , 2019, 210, 94-104.	5.7	27
113	RIG-Iâ€œLike Receptor LGP2 Is Required for Tumor Control by Radiotherapy. <i>Cancer Research</i> , 2020, 80, 5633-5641.	0.4	27
114	Oligometastasis: Past, Present, Future. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 530-538.	0.4	27
115	Concomitant Chemoradiotherapy With Cisplatin, 5-Fluorouracil and Hydroxyurea in Poor-Prognosis Head and Neck Cancer. <i>Laryngoscope</i> , 1992, 102, 630-636.	1.1	25
116	Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1795-1808.	3.2	24
117	4-Hydroxyacetophenone modulates the actomyosin cytoskeleton to reduce metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22423-22429.	3.3	24
118	All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. <i>Science Immunology</i> , 2021, 6, .	5.6	24
119	Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. <i>Clinical Cancer Research</i> , 2020, 26, 4723-4736.	3.2	23
120	Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 5510-5518.	3.2	23
121	Oxidative Cell Membrane Alteration: Evidence for Surfactant-Mediated Sealing. <i>Annals of the New York Academy of Sciences</i> , 1999, 888, 274-284.	1.8	22
122	(Oligo)metastasis as a Spectrum of Disease. <i>Cancer Research</i> , 2021, 81, 2577-2583.	0.4	22
123	Reprogramming of Neutrophils as Non-canonical Antigen Presenting Cells by Radiotherapyâ€œRadiodynamic Therapy to Facilitate Immune-Mediated Tumor Regression. <i>ACS Nano</i> , 2021, 15, 17515-17527.	7.3	22
124	Ultrathin metal-organic layer-mediated radiotherapy-radiodynamic therapy enhances immunotherapy of metastatic cancers. <i>Matter</i> , 2019, 1, 1331-1353.	5.0	20
125	Nanomedicine for Combination Therapy of Cancer. <i>EBioMedicine</i> , 2015, 2, 366-367.	2.7	19
126	ROS modifiers and NOX4 affect the expression of the survivin-associated radio-adaptive response. <i>Free Radical Biology and Medicine</i> , 2018, 123, 39-52.	1.3	19

#	ARTICLE	IF	CITATIONS
127	Stress response genes induced in mammalian cells by ionizing radiation. <i>Radiation Oncology Investigations</i> , 1993, 1, 81-93.	1.3	18
128	Comparison of carboplatin+paclitaxel to docetaxel+cisplatin+5-fluorouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 52-58.	0.8	18
129	Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv278.	3.0	18
130	JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 732-739.	1.9	18
131	Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 17-26.	0.4	18
132	Incidence and implications of oligometastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11512-e11512.	0.8	18
133	Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers. <i>Oncotarget</i> , 2016, 7, 33919-33933.	0.8	18
134	Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1 Resistant Tumors Leading to Tumor Eradication. <i>Cancer Immunology Research</i> , 2017, 5, 127-136.	1.6	17
135	TP53 Mutational Status and ROS Effect the Expression of the Survivin-Associated Radio-Adaptive Response. <i>Radiation Research</i> , 2017, 188, 659-670.	0.7	17
136	DDX39B interacts with the pattern recognition receptor pathway to inhibit NF- κ B and sensitize to alkylating chemotherapy. <i>BMC Biology</i> , 2020, 18, 32.	1.7	16
137	Decoy Receptor DcR1 Is Induced in a p50/Bcl3 Dependent Manner and Attenuates the Efficacy of Temozolomide. <i>Cancer Research</i> , 2015, 75, 2039-2048.	0.4	15
138	Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4493-4500.	3.2	15
139	Role of GADD45a in murine models of radiation- and bleomycin-induced lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L1420-L1429.	1.3	14
140	CDK1 is up-regulated by temozolomide in an NF- κ B dependent manner in glioblastoma. <i>Scientific Reports</i> , 2021, 11, 5665.	1.6	14
141	DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. <i>PLoS ONE</i> , 2014, 9, e102112.	1.1	14
142	More on Cetuximab in Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 2201-2203.	13.9	12
143	Very low doses of ionizing radiation and redox associated modifiers affect survivin-associated changes in radiation sensitivity. <i>Free Radical Biology and Medicine</i> , 2016, 99, 110-119.	1.3	12
144	Concomitant Hydroxyurea, 5-Fluorouracil, and Radiation Therapy for Recurrent Head and Neck Cancer: Early Results. <i>Otolaryngology - Head and Neck Surgery</i> , 1988, 98, 295-298.	1.1	11

#	ARTICLE	IF	CITATIONS
145	Type 3 innate lymphoid cell-derived lymphotoxin prevents microbiota-dependent inflammation. <i>Cellular and Molecular Immunology</i> , 2018, 15, 697-709.	4.8	11
146	Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9573.	1.8	10
147	Antipain-mediated suppression of sister chromatid exchanges induced by an inhibitor of poly (ADP-ribose) polymerase. <i>Environmental Mutagenesis</i> , 1985, 7, 703-709.	1.4	9
148	Monosomy 12p in a radiation-induced germ cell tumor. <i>Genes Chromosomes and Cancer</i> , 1990, 2, 186-190.	1.5	9
149	The Effect of Radiotherapy Dose on Survival in Stage III Non-“Small-Cell Lung Cancer Patients Undergoing Definitive Chemoradiotherapy. <i>Clinical Lung Cancer</i> , 2014, 15, 365-371.	1.1	9
150	Nonmuscle Myosin Light Chain Kinase Activity Modulates Radiation-Induced Lung Injury. <i>Pulmonary Circulation</i> , 2016, 6, 234-239.	0.8	9
151	Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. <i>Clinical Cancer Research</i> , 2021, 27, 5188-5194.	3.2	9
152	How does antiangiogenic therapy affect brain tumor response to radiation?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 232-233.	4.3	8
153	Imaging of tumor clones with differential liver colonization. <i>Scientific Reports</i> , 2015, 5, 10946.	1.6	8
154	Survival outcomes for postoperative chemoradiation in intermediate-risk oral tongue cancers. <i>Head and Neck</i> , 2017, 39, 2537-2548.	0.9	8
155	p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability. <i>Nature Communications</i> , 2020, 11, 5007.	5.8	8
156	Cooperation of genes in HPV16 <i>E6/E7</i>-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. <i>Carcinogenesis</i> , 2020, 41, 1605-1615.	1.3	8
157	Prospective Clinical Investigation of the Efficacy of Combination Radiation Therapy With Immune Checkpoint Inhibition. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1165-1175.	0.4	8
158	Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 825-831.	0.8	7
159	Small Animal IMRT Using 3D-Printed Compensators. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 551-565.	0.4	7
160	The Spectrum of Metastasis: An Opportunity for Cure?. <i>Seminars in Radiation Oncology</i> , 2021, 31, 174-179.	1.0	7
161	Radioresistant tumor cell lines derived from head and neck radiation failures. <i>Head and Neck</i> , 1989, 11, 343-348.	0.9	6
162	Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 625-632.	1.1	6

#	ARTICLE	IF	CITATIONS
163	The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes. <i>Frontiers in Immunology</i> , 2020, 11, 580335.	2.2	6
164	Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 18726-18734.	0.8	6
165	Stereotactic Radiotherapy for Pulmonary Metastases. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2013, 25, 292-299.	0.4	5
166	Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	5
167	STING (or SRC) Like an ICB: Priming the Immune Response in Pancreatic Cancer. <i>Cancer Research</i> , 2019, 79, 3815-3817.	0.4	5
168	Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. <i>Annals of Surgical Oncology</i> , 2022, 29, 4583-4592.	0.7	4
169	p52 signaling promotes cellular senescence. <i>Cell and Bioscience</i> , 2022, 12, 43.	2.1	4
170	Tumor size does not limit radiation-inducible gene therapy in a human xenograft model. <i>Radiation Oncology Investigations</i> , 1995, 3, 238-242.	1.3	3
171	Acute toxicity in radiotherapy of prostate cancer:Results of a randomized study with and without beam's-eye view three-dimensional conformal therapy. <i>Radiation Oncology Investigations</i> , 1996, 4, 231-238.	1.3	3
172	Bugging the intestinal response to radiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 13363-13364.	3.3	3
173	Response Letter: Radiation therapy for COVID-19 pneumopathy. <i>Radiotherapy and Oncology</i> , 2020, 149, 238-239.	0.3	3
174	Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2022, 29, 225-239.	1.6	3
175	Effect of Postradiotherapy Neck Dissection on Nonregional Disease Sites. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 12.	1.2	2
176	Immunoradiotherapy goes club(bing). <i>Nature Cancer</i> , 2021, 2, 871-872.	5.7	2
177	Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers. <i>JAMA Oncology</i> , 2022, 8, 333.	3.4	2
178	Differential retention of tumor- and differentiation-suppressor functions in cells derived from a human squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 1992, 5, 278-285.	1.3	1
179	Evidence for the Use of Multiple Mechanisms by Herpes Simplex Virus-1 R7020 to Inhibit Intimal Hyperplasia. <i>PLoS ONE</i> , 2015, 10, e0130264.	1.1	1
180	Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy. <i>Neoplasia</i> , 2022, 27, 100782.	2.3	1

#	ARTICLE	IF	CITATIONS
181	MUCing around with tumor suppression. <i>Cancer Biology and Therapy</i> , 2008, 7, 1968-1969.	1.5	0
182	Response. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv413.	3.0	0
183	Retuning the Radio in Radiobiology. <i>Journal of the National Cancer Institute</i> , 2018, 110, 325-326.	3.0	0
184	Drugâ€“Radiotherapy Combination Trial Developmentsâ€”Response. <i>Clinical Cancer Research</i> , 2021, 27, 356-356.	3.2	0
185	Dimethylaminomicheliolide Sensitizes Cancer Cells to Radiotherapy for Synergistic Combination with Immune Checkpoint Blockade. <i>Advanced Therapeutics</i> , 2022, 5, 2100160.	1.6	0
186	Anti-Leukemic Activity Is Increased with Low Dose Busulfan and Irradiation: A Preclinical Model. <i>Blood</i> , 2011, 118, 4696-4696.	0.6	0
187	Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intensity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study. <i>Blood</i> , 2013, 122, 3285-3285.	0.6	0
188	Correlation of homologous recombination deficiency in head and neck cancer with sensitivity to PARP inhibition.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6094-6094.	0.8	0
189	LINAC-based intensity modulated total marrow irradiation (TMI) in addition to myeloablative fludarabine/IV busulfan conditioning prior to allogeneic stem cell transplant for high-risk hematologic malignancies: A phase I study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7045-7045.	0.8	0
190	A Phase 1 Study of Total Marrow Irradiation Combined with High-Dose Melphalan for Patients with Relapsed/ Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 4646-4646.	0.6	0